Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730534 · ClinicalTrials.gov registry record · Phase 3
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 17,190
- Enrollment target
NCT01730534: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01730534 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 17,190 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2130% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01730534, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17,190 participants
- Enrollment target
Study Summary
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Primary Outcome
Safety and co-primary efficacy
Interventions
- DRUG Placebo tablet
- DRUG Dapagliflozin 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,190 participants |
| Start Date | 2013-04-25 |
| Est. Completion | 2018-09-11 |
| Phase | Phase 3 |
What the finished NCT01730534 record still lists
NCT01730534 is an interventional study that assigns participants to a tested intervention. Its 17,190 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2130% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT01730534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01730534 about?
NCT01730534 is a clinical study titled "Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events". This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
What is the current status of trial NCT01730534?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17,190 participants. The study started on 2013-04-25. Estimated completion is 2018-09-11.
What interventions are being tested in trial NCT01730534?
The interventions under investigation include: Placebo tablet (DRUG), Dapagliflozin 10 mg (DRUG).
Who is sponsoring clinical trial NCT01730534?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01730534's enrollment target sits among peer trials
17,190 12th of 2000 higher than 1,989 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06245187 · 17,198 participants
Get With the Guidelines Atrial Fibrillation Registry
- NCT06479447 · 17,000 participants · NA
Patient Outcome Reporting for Timely Assessments of Life With Post-Traumatic Stress Disorder
- NCT06948838 · 16,895 participants · NA
Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment
- NCT06272110 · 17,500 participants
Promoting Equitable Access to Language Services in Health and Human Services
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI